DX-88 a recombinant inhibitor of human plasma kallikrein. Evalation of efficacy and safety in patients with hereditary angioedema

被引：0

作者：

Williams, T

Cicardi, M

Bork, K

Gonzalez-Quevedo, T

Caballero, T

机构：

[1] Univ Milan, Dipartimento Med Interna, IRCCS, Osped Maggiore, Milan, Italy

[2] Univ Hautklin, Mainz, Germany

[3] Hosp Univ V del Rocio, Unidad Alergia Ctr Diagnost, Seville, Spain

[4] Hosp Univ La Paz, Serv Alergia, Madrid, Spain

[5] Dyax Corp, Cambridge, MA USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2003年 / 111卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：908 / 908

页数：1

共 50 条

[1] DX-88 a recombinant inhibitor of human plasma kallikrein. Efficacy and safety in hereditary and acquired angioedema
Cicardi, M
Gonzalez-Quevedo, T
Caballero, T
Bork, K
Williams, A
[J]. MOLECULAR IMMUNOLOGY, 2003, 40 (2-4) : 197 - 198
[2] Inhibitor of human plasma kallikrein DX-88 for the treatment of acute attack in a family with hereditary angioedema
Anne, R
Deveras, E
Bracho, F
[J]. BLOOD, 2004, 104 (11) : 113B - 114B
[3] Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema
Caballero, T
López-Serrano, C
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : 476 - 477
[4] Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema - Reply
Beck, TR
Baird, LG
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : 477 - 477
[5] Results of a repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88), a recombinant plasma kallikrein inhibitor, in patients with hereditary angioedema.
Lumry, W.
Li, H.
Schneider, L.
Leflein, J.
Craig, T.
Morrison, J.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : A29 - A29
[6] Anaphylaxis in response to C1 esterase inhibitor in a patient with hereditary Angioedema - Successful treatment with DX-88, a human plasma kallikrein inhibitor
Zingale, Lorenza C.
Zanichelli, Andrea
Deliliers, Daniela Lambertenghi
Cicardi, Marco
[J]. ALLERGY & CLINICAL IMMUNOLOGY INTERNATIONAL-JOURNAL OF THE WORLD ALLERGY ORGANIZATION, 2007, 19 (04): : 159 - 163
[7] Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery
Lehmann, Andreas
[J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (08) : 1187 - 1199
[8] Resolution of bowel obstruction in a patient with hereditary angioedema treated with DX-88 (Ecallantide1), a potent human plasma kallikrein inhibitor:: A case study
Cicardi, Marco
Zingale, Lorenza C.
Zanichelli, Andrea
[J]. MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 160 - 160
[9] DX-88, a novel Kunitz-type inhibitor of human plasma kallikrein with potential therapeutic use.
Mackie, IJ
Lawrie, AS
Purdy, G
Williams, T
Machin, SJ
[J]. BLOOD, 2002, 100 (11) : 88B - 89B
[10] Results of a 2-stage, phase 3 pivotal trial, EDEMA3®:: A study of subcutaneous DX-88 (ecallantide), a plasma kallikrein inhibitor, in patients with hereditary angioedema (HAE)
Levy, R.
McNeil, D.
Li, H.
Hsu, F. I.
Horn, P.
Roberts, J.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S103 - S103

← 1 2 3 4 5 →